Entrada Therapeutics Stock Performance
| TRDA Stock | USD 19.37 0.33 1.73% |
On a scale of 0 to 100, Entrada Therapeutics holds a performance score of 7. The firm shows a Beta (market volatility) of 2.3, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Entrada Therapeutics will likely underperform. Please check Entrada Therapeutics' value at risk, kurtosis, price action indicator, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Entrada Therapeutics' price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Entrada Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating fundamental indicators, Entrada Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.26 | Five Day Return 6.95 | Year To Date Return 25.84 | Ten Year Return (20.29) | All Time Return (20.29) |
1 | Disposition of 941 shares by Wentworth Kory James of Entrada Therapeutics at 15.4234 subject to Rule 16b-3 | 09/04/2024 |
2 | Disposition of 165 shares by Wentworth Kory James of Entrada Therapeutics at 15.126 subject to Rule 16b-3 | 09/05/2024 |
3 | shibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors | 09/17/2024 |
4 | Disposition of 847 shares by Nathan Dowden of Entrada Therapeutics at 16.0 subject to Rule 16b-3 | 09/26/2024 |
5 | Disposition of 600 shares by Natarajan Sethuraman of Entrada Therapeutics at 18.0 subject to Rule 16b-3 | 10/16/2024 |
6 | There Is A Reason Entrada Therapeutics, Inc.s Price Is Undemanding | 10/17/2024 |
7 | Heres Why Momentum in Entrada Therapeutics Should Keep going | 10/31/2024 |
8 | Disposition of 749 shares by Natarajan Sethuraman of Entrada Therapeutics at 18.022 subject to Rule 16b-3 | 11/04/2024 |
9 | Entrada Therapeutics Reports Third Quarter 2024 Financial Results | 11/05/2024 |
10 | Entrada Therapeutics stock target lifted on positive trial data | 11/06/2024 |
11 | Disposition of 6000 shares by Wentworth Kory James of Entrada Therapeutics at 2.1 subject to Rule 16b-3 | 11/11/2024 |
12 | Disposition of 2700 shares by Natarajan Sethuraman of Entrada Therapeutics at 20.0403 subject to Rule 16b-3 | 11/13/2024 |
13 | Insider Sale at Entrada Therapeutics Inc by President of Research Development | 11/14/2024 |
14 | Insider Sale at Entrada Therapeutics Inc by President of Research Development - GuruFocus.com | 11/15/2024 |
15 | Entrada Therapeutics Is a Great Choice for Trend Investors, Heres Why | 11/25/2024 |
| Begin Period Cash Flow | 49.1 M |
Entrada |
Entrada Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,632 in Entrada Therapeutics on August 28, 2024 and sell it today you would earn a total of 272.00 from holding Entrada Therapeutics or generate 16.67% return on investment over 90 days. Entrada Therapeutics is currently generating 0.2955% in daily expected returns and assumes 3.3189% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Entrada, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Entrada Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Entrada Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Entrada Therapeutics, and traders can use it to determine the average amount a Entrada Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.089
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TRDA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.32 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.3 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Entrada Therapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Entrada Therapeutics by adding it to a well-diversified portfolio.
Entrada Therapeutics Fundamentals Growth
Entrada Stock prices reflect investors' perceptions of the future prospects and financial health of Entrada Therapeutics, and Entrada Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Entrada Stock performance.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0695 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | (1.11) % | ||||
| Current Valuation | 324.45 M | ||||
| Shares Outstanding | 37.42 M | ||||
| Price To Book | 1.69 X | ||||
| Price To Sales | 3.31 X | ||||
| Revenue | 129.01 M | ||||
| EBITDA | (321 K) | ||||
| Net Income | (6.68 M) | ||||
| Cash And Equivalents | 244.25 M | ||||
| Cash Per Share | 7.81 X | ||||
| Total Debt | 68.23 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 14.05 X | ||||
| Book Value Per Share | 11.93 X | ||||
| Cash Flow From Operations | 139.8 M | ||||
| Earnings Per Share | 1.44 X | ||||
| Market Capitalization | 712.48 M | ||||
| Total Asset | 469.19 M | ||||
| Retained Earnings | (194.97 M) | ||||
| Working Capital | 210.97 M | ||||
About Entrada Therapeutics Performance
By analyzing Entrada Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Entrada Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Entrada Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Entrada Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.03) | (0.03) |
Things to note about Entrada Therapeutics performance evaluation
Checking the ongoing alerts about Entrada Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Entrada Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Entrada Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 129.01 M. Net Loss for the year was (6.68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Entrada Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Entrada Therapeutics Is a Great Choice for Trend Investors, Heres Why |
- Analyzing Entrada Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Entrada Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Entrada Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Entrada Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Entrada Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Entrada Therapeutics' stock. These opinions can provide insight into Entrada Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Entrada Stock analysis
When running Entrada Therapeutics' price analysis, check to measure Entrada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entrada Therapeutics is operating at the current time. Most of Entrada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Entrada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entrada Therapeutics' price. Additionally, you may evaluate how the addition of Entrada Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |